Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (tha...

The effect of thyroid hormone on the activity of low Km cyclic AMP) phosphodiesterase of the particulate fraction from the kidney was investigated. This enzyme activity increased in the cortex from hypothyroid rats and reverted to the normal level after the subcutaneous administration of L-3,5,3'-triiodothyronine (T3) daily for 3 days. However, this hormone did not affect the enzymes from the n...

Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by erythema and pruritis, affecting over 15 million people in the US. Th2/Th17 cytokines play key role AD pathogenesis, resulting an increased response, disrupted barrier, susceptibility to infections allergen sensitization. Phosphodiesterase 4 (PDE4) cyclic 3’,5’-adenosine monophosphate (cAMP)-specific phospho...

We estimated nucleotide pyrophosphatase and phosphodiesterase I activities in human and rat organs and in body fluids from man and dog. The highest organ activities were found in epididymis, kidney, liver, and intestine. In body fluids, the activity was highest in seminal plasma, followed by intestinal lymph, serum, heart lymph, cerebrospinal fluid, milk, and urine. The ratio nucleotide pyropho...

Avanafil is a medication that was recently approved by the US Food and Drug Administration for the management of erectile dysfunction. Avanafil is a new phosphodiesterase type 5 inhibitor similar to sildenafil and tadalafil. Avanafil was studied in over 1300 patients during clinical trials, including patients with diabetes mellitus and those who had undergone radical prostatectomy, and was foun...

background: sildenafil is a selective inhibitor of phosphodiesterase type 5 (pde5) which currently used for the treatment of erection dysfunction (ed). medicine approved by the fda for treatment of pulmonary hypertension. although there is no evidence of hypercoagulation states being associated with the use of pde5 inhibitors, several animal studies suggest that pde5 inhibitors may cause arteri...

PURPOSE Phosphodiesterase type 5 inhibitors were recently introduced as a new treatment option for men with lower urinary tract symptoms. Safety and clinical effectiveness are well documented but the mode of action is still unclear. We determined and compared the expression of phosphodiesterase type 5 in the spinal cord of normal (sham operated) rats and rats with partial urethral obstruction i...

With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dysfunction in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects and ease of administration, revolutionized the treatment of erectile dysfunction. For women, testosterone administration is the principal treatment for hypoactive sexual desire dis...

in this paper, a general introduction is given, presenting the overactive bladder syndrome (oab) and its impact on the quality of life and economical burden in patients affected. moreover, the anatomy, physiology and histology of the lower urinary tract are discussed, followed by a brief overview on the possible role of prostaglandin (pg) and phosphodiesterase type 5 (pde5) in the urinary bladd...